Scarica l'app Stockscreener
1.21
0.00%
0.00
Dopo l'orario di chiusura:
1.23
0.02
+1.65%
Precedente Chiudi:
$1.21
Aprire:
$1.17
Volume 24 ore:
155.08K
Relative Volume:
1.33
Capitalizzazione di mercato:
$33.93M
Reddito:
-
Utile/perdita netta:
$-49.87M
Rapporto P/E:
-0.6161
EPS:
-1.964
Flusso di cassa netto:
$-19.36M
1 W Prestazione:
-4.72%
1M Prestazione:
+1.68%
6M Prestazione:
+4.31%
1 anno Prestazione:
-30.46%
Intervallo 1D:
$1.11
$1.3295
Intervallo di 1 settimana:
$1.11
$1.33
Portata 52W:
$1.02
$2.40
Rein Therapeutics Inc Stock (RNTX) Company Profile
Nome
Rein Therapeutics Inc
Settore
Industria
Telefono
(737) 802-1989
Indirizzo
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.21 | 33.93M | 0 | -49.87M | -19.36M | -1.964 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2017-07-24 | Iniziato | BofA/Merrill | Buy |
| 2017-07-24 | Iniziato | Jefferies | Buy |
| 2017-07-24 | Iniziato | William Blair | Outperform |
Rein Therapeutics Inc Borsa (RNTX) Ultime notizie
RNTX Forecast, Price Target & Analyst Ratings | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
RNTX Should I Buy - Intellectia AI
Rein 2026 10-K Report: Business Overview, Risk Factors, Pipeline, Competition, and Strategic Partnerships - Minichart
Rein Therapeutics 10-K: $0 Revenue, $0 Gross Profit; Net Loss $49.9M - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Rein Therapeutics (NASDAQ: RNTX) 10-K shifts focus to LTI-03 and flags 2026 funding needs - stocktitan.net
Rein Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Decliners: What makes Rein Therapeutics Inc stock attractive today2026 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Risk Off: Can Rein Therapeutics Inc beat the S P 5002026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Update Recap: Can Rein Therapeutics Inc sustain earnings growthEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Returns Recap: Can RenovoRx Inc expand its profit margins2026 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Will Rein Therapeutics Inc. stock outperform international peersPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Naître et grandir
What technical signals suggest for IDAI stockBond Market & Daily Stock Trend Watchlist - Naître et grandir
How Roundhill ETF Trust Roundhill AMZN stock valuation compares with sector2025 Sector Review & Long-Term Safe Investment Plans - Naître et grandir
Why BILL stock appeals to dividend investorsJuly 2025 Recap & AI Powered Market Entry Strategies - Naître et grandir
Rein Therapeutics Secures Funding and Advances Key Clinical Trial () - aktiencheck.de
With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients - Pulmonary Fibrosis News
Rein Therapeutics doses first patient in IPF trial for LTI-03 - Investing.com Canada
Rein Therapeutics doses first patient in phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis - marketscreener.com
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - GlobeNewswire
Rein Therapeutics Raises $2.3 Million in Private Unsecured Notes With 20% OID, Due by Jun 30, 2026 - TradingView
Chet Holmgren x Nike KD 18 "Thunder & Reign" Releases March 13th - Sneaker Bar Detroit
RNTX Technical Analysis & Stock Price Forecast - Intellectia AI
Rein Therapeutics Inc. announced that it has received $2.3 million in funding - marketscreener.com
White House to host Big Tech after pledge to rein in power costs - Yahoo Finance
Profit Recap: What are the future prospects of Sage Therapeutics Inc2025 Analyst Calls & Daily Entry Point Trade Alerts - baoquankhu1.vn
Rein Therapeutics Inc. announced that it expects to receive $2.3 million in funding - marketscreener.com
Targets Report: What makes Rein Therapeutics Inc stock attractive today2025 Technical Patterns & Smart Swing Trading Alerts - baoquankhu1.vn
Rein Therapeutics Announces Immediate Board Director Resignation - TipRanks
Rein Therapeutics (RNTX) director Aivado resigns from board role - Stock Titan
Quarterly Recap: How cyclical is The Nassau Companies of New York Preferred Securitys revenue streamEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rein Therapeutics Inc. Announces Manuel C. Alves Aivado Decides to Resign as Member of Board of Directors, Effective February 16, 2026 - marketscreener.com
Will Rein Therapeutics Inc. stock split again soon2025 Support & Resistance & Consistent Profit Trading Strategies - mfd.ru
Is Meteoric Resources NL (RNF) stock a buy for dividend portfoliosLayoff News & Verified Momentum Watchlists - mfd.ru
Stock Report: How correlated is Madrigal Pharmaceuticals Inc to the S P500Weekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Why Sterling Infrastructure Inc. (UAO) stock appeals to dividend investors2025 Market Outlook & Free Fast Entry Momentum Trade Alerts - mfd.ru
Is Rein Therapeutics Inc. stock oversold or undervalued2025 Price Action Summary & Daily Stock Trend Watchlist - mfd.ru
RNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Por - GuruFocus
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - The Manila Times
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire
China Warns Banks to Rein in Holdings of US Treasuries - Yahoo Finance
Buy Signal: What is Sotera Health Companys valuation compared to sectorJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
Rein Therapeutics (RNTX) Price Target Increased by 25.00% to 10.20 - Nasdaq
Aug Sentiment: Is Rein Therapeutics Inc a speculative investmentJuly 2025 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 76.0% in January - Defense World
KDA Group (CVE:KDA) Stock Price Up 23.5% – Still a Buy? - Defense World
Rein Therapeutics Inc Azioni (RNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):